St. Jude wins FDA green light for Axium chronic pain device

St. Jude Medical (NYSE:STJ) said today it won FDA premarket approval for its Axium neurostimulator system using dorsal root ganglion stimulation. The device from St. Paul, Minn.-based St. Jude is designed to treat moderate to severe chronic intractable pain of the lower limbs in adult patients with complex regional pain syndrome. “The approval of St. Jude Medical’s DRG neurostimulation system represents an exciting new option for me to deploy in the fight against the focal and intractable chronic pain syndromes facing my patients every day. For the large and growing numbers of under-treated patients suffering from complex regional pain syndromes – like those resulting from total knee arthroscopy, foot surgery or hernia surgery – DRG stimulation can offer improved, long-lasting relief,” Dr. Timothy Deer of Charleston, W.V.’s Center for Pain Relief said in prepared remarks. Through stimulation of the dorsal root ganglion, a spinal structure populated with sensory nerves that transfer information to the brain via the spinal cord, clinicians are able to treat the specific areas of the body where pain occurs, St. Jude said. The device could allow pain relief to patients with neuropathic conditions currently underserved by traditional spinal cord stimulation, the company said. “St. Jude Medical is focused on providing physicians with more options to treat patients suffering from a wide range of chronic pain conditions, no matter where in the body th...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Business/Financial News Neurological Neuromodulation/Neurostimulation St. Jude Medical Source Type: news